Prosecution Insights
Last updated: April 19, 2026

Newave Pharmaceutical Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
2
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18268632 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES BRAUN, MADELINE E 1624 Non-Final OA Jun 21, 2023
18020980 DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF ENGLISH, CONNOR KENNEDY 1625 Final Rejection Feb 13, 2023
17798904 HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR PECKHAM, RICHARD GRANT 1627 Non-Final OA Aug 11, 2022
17764329 INHIBITOR OF BTK AND MUTANTS THEREOF STOCKTON, LAURA LYNNE 1626 Final Rejection Mar 28, 2022
17764285 CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS HEASLEY, MEGHAN CHRISTINE 1626 Non-Final OA Mar 28, 2022

Managing Newave Pharmaceutical Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month